Conference
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
Abstract
BACKGROUND: Heat shock protein 27 (Hsp27) is a chaperone protein that regulates cell survival via androgen receptor and other signaling pathways, thereby mediating cancer progression. Apatorsen (OGX-427) is a 2'-methoxyethyl-modified antisense oligonucleotide that inhibits Hsp27 expression. This study evaluated the safety profile and recommended phase II dosing of apatorsen in patients with advanced cancer.
PATIENTS AND METHODS: Patients with …
Authors
Chi KN; Yu EY; Jacobs C; Bazov J; Kollmannsberger C; Higano CS; Mukherjee SD; Gleave ME; Stewart PS; Hotte SJ
Volume
27
Pagination
pp. 1116-1122
Publisher
Elsevier
Publication Date
June 2016
DOI
10.1093/annonc/mdw068
Conference proceedings
Annals of Oncology
Issue
6
ISSN
0923-7534
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overDiazepamDose-Response Relationship, DrugDrug-Related Side Effects and Adverse ReactionsGene Expression Regulation, NeoplasticHSP27 Heat-Shock ProteinsHeat-Shock ProteinsHumansMaleMiddle AgedMolecular ChaperonesNeoplastic Cells, CirculatingOligonucleotides, AntisenseProstatic Neoplasms, Castration-Resistant